Hims & Hers Health, Inc. (NYSE:HIMS) Receives $37.23 Consensus Target Price from Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average rating of “Hold” by the fifteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.23.

A number of equities research analysts have recently weighed in on the company. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Bank of America lifted their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research note on Thursday, February 20th. Citigroup boosted their price objective on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a report on Tuesday, February 25th. Finally, Leerink Partners raised their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 85,561 shares of Hims & Hers Health stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $31.01, for a total value of $2,653,246.61. Following the completion of the transaction, the chief operating officer now owns 630,986 shares of the company’s stock, valued at approximately $19,566,875.86. The trade was a 11.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the sale, the chief executive officer now directly owns 109,956 shares in the company, valued at approximately $3,256,896.72. The trade was a 41.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,062,011 shares of company stock worth $36,892,724. 17.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Crewe Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth $28,000. Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 9.8 %

Shares of HIMS opened at $40.65 on Friday. The company has a 50 day moving average of $36.83 and a two-hundred day moving average of $26.99. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market cap of $9.03 billion, a price-to-earnings ratio of 92.39 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. On average, sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.